These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28060766)

  • 1. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
    Segovia C; Martínez-Fernández M; Dueñas M; Rubio C; López-Calderón FF; Costa C; Saiz-Ladera C; Fernández-Grajera M; Duarte J; Muñoz HG; de la Rosa F; Villacampa F; Castellano D; Paramio JM
    Oncotarget; 2017 Feb; 8(6):10531-10542. PubMed ID: 28060766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
    Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
    Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
    Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.
    Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J
    Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
    Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
    Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer.
    Liu X; Cui J; Gong L; Tian F; Shen Y; Chen L; Wang Y; Xia Y; Liu L; Ye X; Wang M; Liu G; Jiang B; Shao C; Zou Y; Gong Y
    Oncogene; 2020 Apr; 39(17):3588-3603. PubMed ID: 32127645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling.
    Guo Y; Ying L; Tian Y; Yang P; Zhu Y; Wang Z; Qiu F; Lin J
    FEBS J; 2013 Sep; 280(18):4531-8. PubMed ID: 23815091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of CircRNA BCRC4 regulates cell apoptosis and MicroRNA-101/EZH2 signaling in bladder cancer.
    Li B; Xie F; Zheng FX; Jiang GS; Zeng FQ; Xiao XY
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):886-890. PubMed ID: 29270748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
    Le Goux C; Vacher S; Schnitzler A; Barry Delongchamps N; Zerbib M; Peyromaure M; Sibony M; Allory Y; Bieche I; Damotte D; Pignot G
    Sci Rep; 2020 Oct; 10(1):16641. PubMed ID: 33024200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
    Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
    HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells.
    Chen Y; Xie H; Zou Y; Lai X; Ma L; Liu Y; Li J
    Mol Biosyst; 2017 Jul; 13(8):1597-1607. PubMed ID: 28671703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR‑92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2.
    Liu F; Sang M; Meng L; Gu L; Liu S; Li J; Geng C
    Int J Oncol; 2018 Oct; 53(4):1505-1515. PubMed ID: 30066891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription.
    Wang M; Guo C; Wang L; Luo G; Huang C; Li Y; Liu D; Zeng F; Jiang G; Xiao X
    Cell Death Dis; 2018 Feb; 9(2):238. PubMed ID: 29445179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
    Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH
    Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
    Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
    Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
    Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
    Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of microRNA-218 via EZH2-mediated H3K27 trimethylation is involved in malignant transformation of HBE cells induced by cigarette smoke extract.
    Wang B; Liu Y; Luo F; Xu Y; Qin Y; Lu X; Xu W; Shi L; Liu Q; Xiang Q
    Arch Toxicol; 2016 Feb; 90(2):449-61. PubMed ID: 25526925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.